title: Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry.
abstract: BACKGROUND
  The effectiveness of sirolimus-eluting stents in unselected patients treated in the daily practice is currently unknown.
  
  
  RESULTS
  Sirolimus-eluting stent implantation has been used as the default strategy for all percutaneous procedures in our hospital as part of the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Consecutive patients with de novo lesions (n=508) treated exclusively with sirolimus-eluting stents (SES group) were compared with 450 patients who received bare stents in the period just before (pre-SES group). Patients in the SES group more frequently had multivessel disease, more type C lesions, received more stents, and had more bifurcation stenting. At 1 year, the cumulative rate of major adverse cardiac events (death, myocardial infarction, or target vessel revascularization) was 9.7% in the SES group and 14.8% in the pre-SES group (hazard ratio [HR], 0.62 [95% CI, 0.44 to 0.89]; P=0.008). The 1-year risk of clinically driven target vessel revascularization in the SES group and in the pre-SES group was 3.7% versus 10.9%, respectively (HR, 0.35 [95% CI, 0.21 to 0.57]; P<0.001).
  
  
  CONCLUSIONS
  Unrestricted utilization of sirolimus-eluting stents in the "real world" is safe and effective in reducing both repeat revascularization and major adverse cardiac events at 1 year compared with bare stent implantation.
authors.affiliation: Erasmus Medical Center, Thoraxcenter, Rotterdam, The Netherlands.
authors.forename: Pedro A
authors.initials: PA
authors.lastname: Lemos
authors.forename: Patrick W
authors.initials: PW
authors.lastname: Serruys
authors.forename: Ron T
authors.initials: RT
authors.lastname: van Domburg
authors.forename: Francesco
authors.initials: F
authors.lastname: Saia
authors.forename: Chourmouzios A
authors.initials: CA
authors.lastname: Arampatzis
authors.forename: Angela
authors.initials: A
authors.lastname: Hoye
authors.forename: Muzaffer
authors.initials: M
authors.lastname: Degertekin
authors.forename: Kengo
authors.initials: K
authors.lastname: Tanabe
authors.forename: Joost
authors.initials: J
authors.lastname: Daemen
authors.forename: Tommy K K
authors.initials: TK
authors.lastname: Liu
authors.forename: Eugene
authors.initials: E
authors.lastname: McFadden
authors.forename: Georgios
authors.initials: G
authors.lastname: Sianos
authors.forename: Sjoerd H
authors.initials: SH
authors.lastname: Hofma
authors.forename: Pieter C
authors.initials: PC
authors.lastname: Smits
authors.forename: Willem J
authors.initials: WJ
authors.lastname: van der Giessen
authors.forename: Pim J
authors.initials: PJ
authors.lastname: de Feyter
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D023903:Coronary Restenosis / Q000453:epidemiology / Q000517:prevention & control*; D005260:Female; D006331:Heart Diseases / Q000453:epidemiology; D006801:Humans; D008297:Male; D009426:Netherlands / Q000453:epidemiology; D012042:Registries; D020123:Sirolimus / Q000008:administration & dosage* / Q000627:therapeutic use; D015607:Stents / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D020123:Sirolimus